GEN reports on ocular therapeutics targeting the retina

September 10, 2012
Genetic Engineering & Biotechnology News cover image. GEN is published 21 times per year. Credit: ©2012, Mary Ann Liebert, Inc., publishers

Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, there is a critical need for new remedies, according to a recent issue of GEN.

"As increasing numbers of baby-boomers continue to grow older, many will have to deal with eye diseases such as age-related macular degeneration," said John Sterling, Editor-in-Chief of GEN. "Some estimates put the current AMD and diabetic retinopathy drug segment of the market at $3 billion, and this is expected to increase to about $5 billion in two years."

Standard therapy has been Genentech's VEGF inhibitors Lucentis and the off-label use of Avastin®. Regeneron, in collaboration with Bayer HealthCare, is challenging these drugs with a similar VEGF inhibitor, Eyela. The FDA approved the drug last November for wet AMD.

In another approach, Acucela is in Phase II trials using visual cycle modulators to lighten the metabolic load on the retina by reducing the activity of the rod visual system. This protects the retina from light damage, improves retinal vasculature, and reduces the accumulation of A2E and other retinal-related toxic by-products.

GlaxoSmithKline has two drugs in Phase II trials for ocular therapy: darapladib, an oral Lp-PLA2 inhibitor for diabetic macular edema, and Votrient®, a multi-kinase angiogenesis inhibitor in eye drop form for AMD. Early-stage work also is under way for neovascular AMD, dry AMD, diabetic retinopathy, diabetic macula edema, uveitis, and , as well as for technologies for drug delivery.

Explore further: FDA approves drug to treat diabetic macular edema

Related Stories

FDA approves drug to treat diabetic macular edema

August 13, 2012
The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, ...

Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases

July 27, 2012
Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because ...

Recommended for you

Researchers identify potential biomarkers of age-related macular degeneration

September 12, 2017
Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through special laboratory tests, according to a new study led by AMD researchers based at Massachusetts ...

Researchers unlock regenerative potential of cells in the mouse retina

August 28, 2017
Cells within an injured mouse eye can be coaxed into regenerating neurons and those new neurons appear to integrate themselves into the eye's circuitry, new research shows. The findings potentially open the door to new treatments ...

Antioxidant supplement cost saving and effective for degenerative eye disease

August 24, 2017
A supplement that combines antioxidants with zinc and copper is a relatively inexpensive and effective means of halting the progression of a certain type of degenerative eye disease, concludes research published online in ...

Researchers identify key compounds to resolve abnormal vascular growth in AMD

August 21, 2017
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers. ...

World's blind population to soar: study

August 3, 2017
The world's blind will increase threefold from about 36 million today to 115 million in 2050 as populations expand and individuals grow ever older, researchers said Thursday.

Simulations signal early success for fractal-based retinal implants

July 27, 2017
Computer simulations of electrical charges sent to retinal implants based on fractal geometry have University of Oregon researchers moving forward with their eyes focused on biological testing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.